🔗 Share this article

Government ministers and leading parliamentarians have raised concerns that the United Kingdom's series of deals with Donald Trump are "lacking a solid foundation." This comes after revelations that a recently announced deal on medicines, which pledges zero tariffs in exchange for the NHS facing higher prices, lacks any formal legal text beyond limited headline terms outlined by government press releases.

An Agreement in Principle Only

The arrangement concerning medicines, promoted as a "landmark" achievement, exists as an "agreement in principle" without detailed provisions. Observers point out that the official announcements from the UK and US governments frame the deal in sharply different terms. The British version focuses on securing "zero per cent tariffs" as a unique achievement, while the American announcement concentrates on the agreement for the NHS to pay higher prices for new medications.

"We face a genuine possibility that the UK government has promised concessions to raise drug prices in return for little more than a verbal promise from President Trump," said David Henig, a trade expert. "History shows he has form for not keeping promises."

Broader Instability and a Paused Tech Deal

Concerns have been intensified by Washington's recent decision to suspend the £31bn "tech prosperity deal", which was previously called "a transformative pact" in the bilateral relationship. The US pointed to a insufficient movement from the UK on addressing wider trade issues as the reason for the pause.

Additionally, concessions secured for British farmers as part of an initial accord have yet to be formally ratified by the US, despite a fast-approaching January deadline. "Our understanding is that the US has not yet signed off the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

Behind the scenes, ministers have expressed concerns that the government's agreements with the US are unstable and unpredictable. One minister described the series of agreements as "resting on shaky ground," while another described the situation as the "prevailing condition" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, stated: "Perhaps most shocking than Trump's temper tantrums is the UK government's optimistic assumption that his administration is a reliable partner. The NHS is not a bargaining chip."

Official Reassurances and Concrete Outcomes

Officials have attempted to minimize the possibility of the US reneging on the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been pushing for the agreement, seeking certainty on imports and pricing, making it less abstract than the paused tech deal.

Officials concede that volatility is a feature of dealing with the current US leadership. However, they maintain that the UK has achieved real benefits for businesses, such as preferential tariff rates compared to other nations. "The fact we have 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a concrete advantage," one official said.

Yet, delays have emerged in carrying out the initial US-UK accord. Promised access for British beef have not materialized, and the commitment to "eliminate duties on UK metals" has remains unmet, with tariffs staying at 25%.

Moving forward, the two sides have scheduled to restart talks on the paused tech prosperity deal in January, following what were described as "constructive" meetings between UK and US officials in Washington.